Modality
mRNA
MOA
IL-13i
Target
TROP-2
Pathway
Angiogenesis
Melanoma
Development Pipeline
Preclinical
Apr 2018
→ Sep 2029
PreclinicalCurrent
NCT08314519
1,160 pts·Melanoma
2021-04→2029-09·Recruiting
NCT03224728
2,440 pts·Melanoma
2018-04→2025-01·Not yet recruiting
3,600 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-241.2y agoInterim· Melanoma
2029-09-123.5y awayInterim· Melanoma
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Not yet…
Preclinical
Recruit…
Catalysts
Interim
2025-01-24 · 1.2y ago
Melanoma
Interim
2029-09-12 · 3.5y away
Melanoma
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08314519 | Preclinical | Melanoma | Recruiting | 1160 | Biomarker |
| NCT03224728 | Preclinical | Melanoma | Not yet recr... | 2440 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 |